At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
ASP-1001 nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC)
In Brief
A Phase 3 clinical trial evaluating ASP-1001 nasal spray and Placebo for ASP-1001 for Allergic Rhinitis. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
CollaboratorsAsphelia Pharmaceuticals
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartJan 2010
Primary CompletionSep 2010
Study CompletionDec 2010
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.6 years ago
Interventions
ASP-1001 nasal spraydrug
2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
Placebo for ASP-1001drug
2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.